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David R. Rubinow, and Trey Sunderland 
Decreased cerebrospinal fluid (CSF), somatostatinlike immunoreactivity (SU) and al- 
terations in the CSF monamine metabolites 3-methoxy-4-hydro~p~nylethylglycol (MHPG), 
5-hydroxyindoleacetic acid (5-HIAA), and homovaniUic acid (HVA) have been reported 
in patients with probable Alzheimer' s disease (AD) and in patients with major depression. 
In this study, we found CSF SU to be significantly lower in a large group of  AD patients 
(n = 60) and in a group of age-matched patients with major depression (n = 18) as 
compared with normal controls (n = 12). Mean CSF, MHPG, 5-HIAA, and HVA levels 
were not significantly different among diagnostic groups. Within a group of "depressed" 
AD patients, CSF levels of S-HIAA showed a significant positive correlation (p = 0.03) 
with CSF SU; a similar relationship was found within the group of patients with major 
depression. Further exploration of  the relationship between the somatostatin and serotonin 
systems may provide clues as to how neuropeptides interact with monoamine neurotrans- 
miners and what role they have in depression. 
Introduction 
Decreased somatostatinlike immunoreactivity (SLI) has been a consistent finding in _many 
studies of the cerebrospinal fluid (CSF) and brains of patients with Alzheimer's disease 
(AD) (Davies et al 1980; Francis et al 1984; Sunderland et al 1987; Davis et al 1988), 
as well as in the CSF of patients with major depression (Rubinow et al 1983; Bissette et 
al 1986). In normal brain the highest concentrations of the tetradecapeptide, somatostatin, 
exist in the hypothalamus and limbic system, including the amygdala and hippocampus, 
those areas of the brain thought to be especially involved in affective and cognitive 
functions. In the central nervous system (CNS), somatostatin functions as a neuromo- 
dulator, if not a neurotransmitter (Rubinow et al 1983). CSF SLI is thought to reflect 
brain SLI as reviewed by Rubinow (1986). 
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Many interactions between somatostatin and the monoamine neurotransmitters have 
been documented (see Rubinow 1986 for review). While most discussions of AD focus 
on the cholinergic system deficits (Davies and Maloney 1976; Whitehouse et al 1982), 
alterations have been reported in other neurotransmitter systems (Gottfries 1985), espe- 
cially the noradrenergic (Bondareff et al 1982; Zweig et al 1988) and serotonergic systems 
(Mann and Yates 1982; Cross et al 1984; Crow et al 1984; Yamamoto and Hirano 1985; 
Baker and Reynolds 1989; Sparks 1989); the data have been less consistent for the 
dopaminergic system (Soiainen et al 1981; Gottfries 1985). Alterations in these mono- 
amine neurotransmitter systems have also been documented in the brains and CSF of 
patients with major depression (Asberg et al 1984; Roy et al 1985; Mann et al 1986; 
Yates et al 1990), and the monoaminergic theory remains one of the prime etiological 
theories of depression (Rothschild 1988). 
Depressed mood is increasingly recognized to be an important symptom in AD patients; 
most studies estimate that from 17% to 50% of these patients have significant depression 
at some time during the course of the disease (Reding et al 1985; Reifler et al 1986). 
AD patients with major depression have been found to have significantly more degen- 
eration in the locus ceruleus and substantia nigra than nondepressed AD patients (Zubenko 
and Moossy 1988). Similar findings in the locus ceruleus were found in another study 
(Zweig et al 1988), which also found that AD patients with major depression had sig- 
nificantly fewer neurons in the central superior (raphe) nucleus, and a trend for such a 
loss in the dorsal raphe nucleus. Zubenko and coworkers (1990) recently reported that 
demented patients with major depression had a ten-fold decrease of cortical norepineph- 
rine, an increase in dopamine levels in entorhinal cortex, and a decrease in serotonin that 
approached significance in frontal cortex. 
Studies in animals have shown that somatostatin affects many behavioral functions, 
including sleep, appetite, circadian rhythm, motor activity, and pain sensitivity (functions 
that are commonly disrupted in depression) (Reichlin 1982; Rubinow et al 1983). Because 
of the overlapping cognitive and behavioral symptoms and abnormal biological measures 
in AD and major depression and earlier work showing alterations in CSF SLI and mono- 
amine levels in both AD and elderly depression (Sunderland et al 1987; Davis et al 1988), 
we sought to determine the relationship between CSF SLI, CSF monoamines, measures 
of depression, and measures of dementia severity in these populations. 
Methods  
Subjects 
Sixty patients with AD (mean ± SD age = 66.2 ± 8.7 years; 32 women, 28 men), 18 
patients with major depression (64.6 _+ 9.9 years; 12 women, 6 men), and 12 normal 
controls (65.8 ± 10.7 years; 4 women and 8 men) were included in the study. All patient~ 
and controls were studied as inpatients at the National institute of Mental Health (NIMH). 
Primary degenerative dementia of the Alzheimer type and major depression were diag- 
nosed according to DSM-IH-R criteria (American Psychiatric Association 1987). Some 
AD patients had significant depressive symptoms and may have had a prior history of 
depression. Symptoms of depression in these patients were considered a secondary phe- 
nomenon, with dementia being the primary diagnosis. Patients with serious medical 
problems were excluded from the study. Normal controls were screened to exclude those 
with a personal or family history of any significant medical, cognitive, or psychiatric 
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disorder. Normal controls were recruited from the community and were paid for their 
participation. All subjects were free of centrally active drags for at least 3 weeks before 
the study. All subjects gave written informed consent. For AD patients, a relative also 
signed the consent form. 
Rating Scales 
Patients with AD were evaluated with the Dementia Mood Assessment Scale (DMA$) 
(Sunderland et al 1988a, 1988b), a 24-item scale in which the first 17 items are designed 
to measure depression in dementia (DMAS-17) and the last 7 items to measure cognitive 
and functional impairment. The DMAS-17 has some questions that are similar to those 
on the Hamilton Depression Scale (Hamilton 1960), but the two scales are not equivalent 
(Sunderland et al 1988a). AD patients were also evaluated with the modified Bunney- 
Hamburg Global Behavioral Rating Scales (Bunney and Hamburg 1963; Sunderland et 
al 1988a) to rate different aspects of behavior, mood, and impairment, with scores ranging 
from 0 (no impairment) to 13-15 (very severe). Patients diagnosed with major depression 
were rated with the Hamilton Depression Scale as well as the Bunney-Hamburg Global 
Behavioral Rating Scales. Dementia severity was rated using the Global Deterioration 
Scale (GDS) (Reisberg et al 1982) and the Clinical Dementia Rating Scale (CDR) (Hughes 
et al 1982). 
CSF Measures 
Lumbar punctures (LPs) were done between 8:00-9:00 AM on subjects in the :ateral 
decubitus position, after an overnight fast, and after at least 3 days on a low monoamine 
diet. Subjects were on t~ed-rest prior to the LP, except for voiding. The 26th ml of 
collected CSF was immediately frozen without preservatives on dry ice and then stored 
at - 70°C for later measurement of SLI. The 10th through 15th mls of each CSF sample 
were frozen at -70°C and used to measure the neurotra:smitter metabolites 3-methoxy- 
4-hydroxyphenylethylglycol (MHPG), 5-hydroxyindoleacetic acid (5-HIAA), and homo- 
vaniUic acid (HVA) as described elsewhere (Scheinin et al 1983). All monoamines were 
assayed in the Laboratory of Clinical Science, NIMH. The SLI radioimmunoassay was 
done by the Section on Behavioral Endocrinology, NIMH and used ~I-tyrosine-l-so- 
matostatin, rabbit antisomatostatin antiserum (kindly provided by Dr. Seymour Reichlin, 
Tufts University), synthetic cyclic somatostatin standards, and charcoal separation, and 
was performed using procedures described elsewhere (Patel et al 1977). Assay sensitivity 
is 1 pg/tube, with an EDso of 8.6 pg/tube. The antisomatostatin antibody used is directed 
toward the midportion of the tetradecapeptide, so it recognizes N-terminal extensions of 
somatostatin-14, such as somatostatin-28. Samples from AD, depressed, and normal 
subjects were run in the same assays. The intraassay coefficient of variation was about 
6%; the interassay coefficient of variation for this assay is 12%-15%. 
Data Analysis 
CSF SLI and monoamine levels were compared between diagnostic groups by one-way 
ANOVA and post hoc Bonferroni t-tests. Pearson's product-moment correlations were 
used to explore potential relationships among measures of mood, dementia severity, CSF 
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Table 1. Demographic and Clinical Data ° 
Alzheimer patients b Depressed patients Normal controls 
Parameter (n = 60) ( n - -  18) (n = 12) 
Age (years) 66.2 _ 8.7 64.6 _ 9.9 
Gender 32F, 28M 12F, 6M 
Illness duration (years) 3.8 -4- 2.6 
Age of onset (years) 62.2 4- 9.0 
Dementia severity 
Global Deterioration Scale 4.5 _ 1.0 
Clinical Dementia Rating Scale 1.7 4- 0.6 
Dementia Mood Assessment Scale 
17-item 23.0 _ 9.9 
Hamilton Depression Scale 
17-item 22.4 _ 7.1 
24-item 30.0 -4- 8.6 
Bunney-Hamburg Global Scales 
Depression 4.3 4- 1.8 6.9 4- 2.1 
Sadness ~ :~.2 4- 2.2 1.9 4- 2.2 
Anxiety 4.8 4- 1.6 6.6 4- 1.4 
65.8 - 10.7 
4F, 8M 
aValues are mean - SD. 
qqot all patients had all ratings. 
monoamine metabolites, and CSF SLI. To explore the relationship between CSF SLI and 
CSF monoamines in AD patients with affective symptoms, the AD group was divided a 
priori into "depressed" and "nondepressed," and "anxious" and "nonanxious" groups 
based on scores from the DMAS-17 and the Global Depression and Global Anxiety 
Scales. The scores differentiating "depressed" and "nondepressed" patients were based 
on the mean scores of those scales in a prior publication which established the validity 
of the use of those scales in AD patients (Sunderland, et al 1988a). Patients with scores 
greater than or equal to the mean in that prior study (scores of --> 25 on the DMAS-17 
and - 5 on the Global Depression and Anxiety Scales) were considered to have signif- 
icantly more depressive or anxious symptoms than those with scores that were less than 
the mean. Data are presented as the mean -+ SD. 
Results 
Demographic and clinical characteristics of the subjects are summarized in Table 1. The 
CSF SLI levels of 60 patients with probable AD and the group of 18 elderly depressives 
was decreased significantly fi'om that of the age-matcbed controls (df = 2,~;7, F = 
11.42, p < 0.001) (see Table 2). CSF SLI levels differed significantly between the 
"depressed" and "nondepressed" AD patients (Table 2). CSF 5-HIAA did not differ 
significantly between diagnostic groups (df = 2,85, F = 2.41, p < 0.10) (Table 2), 
nor did CSF MHPG or HVA levels (df = 2,84, F = 2.24, p < 0.11 and df = 2,85, 
F = 0.14, p < 0.87, respectiLvely) (Table 2). The CSF 5-HIAA levels among lSe major 
depression patients, the "depressed" AD patients and the "nondepressed" AD patients 
did not differ significantly (~Lf = 2,59, F = 2.353, p < 0.20) (Table 2). Mean CSF 
MHPG and HVA levels also did not differ significantly among these 3 groups ~df = 
2,59, F = 2.35, p < 0.10 and df = 2,59, F = 2.28, p < 0. ! 1, respectively'). 
In the overall group of AD patients, there was no significan~ coael~.tion between any 
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Table 2. Mean  Levels  (+_ SD)  o f  CSF  Somatostat inl ike Immunoreac t iv i ty  and  C S F  M o n o a m i n e  
Metabol i tes  
SLI 5-HIAA MHPG HVA 
Group (n) (pg/ml) (pmol/ml) (pmol/ml) (pmol/ml) 
Alzheimer's (60) 37.2 --- 15.5" 93.0 - 30.9 51.3 "4" 16.0 187.9 +_ 74.1 
"Depressed" (18)* 32.4 - 15.5 b 92.0 - 36.0 50.1 - 14.6 166.3 _ 65.8 
"Nondepressed" (26)* 42.0 -_4-_ 15.6 100.2 _ 28.5 50.3 _ 16.4 213.7 _ 69.0 
Major Depression (18) 45.1 +- 15.5 a'c 112.1 _.+ 37.0 60.8 +_ 20.9 190.2 +_ 83.5 
Controls (12) 60.2 _ 16.1 94.5 ___ 34.3 51.1 _ 14.7 201.6 "4- 66.4 
aDifferent from controls, p < 0.001. 
bDifferent from "nondepressed" AD patients, p < 0.03. 
cDifferent from "depressed" AD patients, p < 0.01. 
*44/60 AD patients were evaluated with depression ratings. 
of the CSF monoamine metabolites and SLI. When the AD group was divided into 
"depressed" and "nondepressed" 5-HIAA was the only metabolite to correlate significantly 
with SLI in the group of "depressed" AD patients as well as in the group of patients with 
major depression (r = 0.49, p < 0.03, n = 20 and r = 0.55, p < 0.02, n = 18, 
respectively) (Figures 1 and 2). A similar relationship was found between SLI and 5- 
HIAA (r = 0.40, p < 0.04, n = 26) (and not MHPG and HVA) in the group of"anxious" 
AD patiems, and also in "anxious" patients with major depression (r = 0.54, p < 0.04, 
n = 12). Neither CSF SLI nor 5-HIAA correlated with measures of dementia severity. 
Comment 
In our study, a significant positive relationship between CSF SLI and CSF 5-HIAA was 
found within a group of depressed AD patients and within a group of patients with major 
depression; this relationship was consistent across the different scales used to assess 
mood. The other monoamine metabolites examined, MI-IPG and HVA, showed no such 
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Figure 1. Correlation between CSF SLI 
and CSF 5-HIAA in "depressed" AD 
patients (r = 0.49;p <0.03; n = 20). 
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Figure 2. Correlation between CSF SLI 
and CSF 5-HIAA in patients with ma- 
jor depression (r = 0.55; p <0.22; n 
= 1 8 ) .  
matostatin related to depressed and anxious mood in both these patient groups. The finding 
of this relationship on rating scales designed to measure depressed mood (the DMAS 17- 
item and the Global Depression Scale) and anxiety (Global/mxiety Scale) is consistent 
with the frequent coexistence of these symptoms in patients with major depression, 
especially in the elderly (Salzman 1990). 
Prior studies of the CSF and brains of AD patients have., also suggested a relationship 
between serotonin and somatostatin, though in none of these studies was depressed mood 
or the presence of major depression evaluated. In one study, decreased numbers of 
serotonin receptors correlated with decreased SH concenI~ations in the cortices of AD 
patients (Beal et al 1985). A significant correlation between decreased 5-HT2 (serotonin) 
receptor binding and SLI in temporal and frontal cortices of AD patients has also been 
reported (Cross et al 1984). In another study, decreased CS]F SLI concentrations in AD 
patients paralleled decreased CSF 5-HIAA and HVA conccnlrations (Francis et al 1984). 
In depressed patients, the relationship between decreased SLI levels and CSF mono- 
amines has been inconsistent. In a study of patients with major depression, Rubinow and 
coworkers found a significant positive correlation between CSF SLI and CSF 5-HIAA 
in seven patients, a positive correlation with MHPG in a small number of patients, and 
a significant negative correlation between SLI and norepinephrine in 16 patients (Rubinow 
et al 1983). In a previous study, we found no such relationship in 20 older patients 
diagnosed with major depression (Sunderland et al 1987). In a study of 85 patients with 
major depression, Agren and Lundqvist found that SLI correlated negatively with 
MHPG/HVA (Agren and Lundqvist 1984). Bissette et al (1986) found no correlation 
between CSF SLI and monoamines in 29 patients with major depression. Small numbers 
of subjects, different diagnostic criteria, different symptom and demographic profiles, 
different rating scales, and different assay methods may have contributed to these different 
findings and the lack of a clear relationship between CSF monoamines and CSF SLI. 
In AD, loss of 5-HT2 receptors may be an early change in the pathological process 
(Cross et al 1984). Studies of SLI indicate that changes in the somatostatin system also 
appear to occur early (Roberts et al 1985; Nakamura and Vincent 1986). Our data support 
that changes in these systems occur early, in that neither SLI or 5-HIAA correlated with 
age, dementia severity, or duration of dementia symptoms. Depression can occur early 
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in the course of AD and can even be an initial symptom (Reding et al 1985; Reifler et 
al 1986). Whether there is a relationship between early depressive symptoms (some of 
our "depressed" patients were not just beginning the course of their illness) and deficits 
in the somatostatin and/or serotonin systems is open for future studies. The study of 
cortical somatostatin and 5-HT2 receptors may also provide clues as to which neurons 
are susceptible to the pathological processes in AD and why, in that both are thought to 
be located predominantly on intrinsic neurons. The primary damage in these systems is 
thought to be in the termina~ fields, especially in the temporal cortex and hippocampus, 
areas of the brain that are known to be affected early in AD (Cross et al 1984; Roberts 
et al 1985; Nakamura and Vincent 1986). Further studies of the relationship between the 
somatostatin and serotonin systems may provide clues as to how neuropeptides interact 
with monoamine neurotransmitters and what role those interactions have in AD and in 
depression. 
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